Literature DB >> 20160055

Evaluation of standard chemotherapy in the guinea pig model of tuberculosis.

Diane J Ordway1, Crystal A Shanley, Megan L Caraway, Eileen A Orme, Daniel S Bucy, Laurel Hascall-Dove, Marcela Henao-Tamayo, Marisa R Harton, Shaobin Shang, David Ackart, Susan L Kraft, Anne J Lenaerts, Randall J Basaraba, Ian M Orme.   

Abstract

The purpose of this study was 2-fold. First, we evaluated standard chemotherapy in the guinea pig model of tuberculosis to determine if this animal species could productively be used for this purpose. Second, given the similarities of the pathology of disease in guinea pigs and humans, we wished to evaluate additional parameters, including magnetic resonance imaging, microscopy, and cytokine expression and lymphocyte phenotypes, in response to an infection treated with drug therapy. This study shows that conventional rifampin-isoniazid-pyrazinamide chemotherapy significantly decreased the numbers of the highly virulent Erdman K01 strain of Mycobacterium tuberculosis, with most of the bacilli being eliminated in a month. Despite this result, bacteria could still be detected in the lungs and other tissues for at least another 3 to 4 months. Resolution of the nonnecrotic granulomas in the lungs and lymph nodes could be clearly visualized by magnetic resonance imaging at the macroscopic level. Microscopically, the majority of the pulmonary and extrapulmonary inflammation resolved spontaneously, leaving residual lesions composed of dystrophic calcification and fibrosis marking the site of necrosis of the primary lesion. Residual calcified lesions, which were also associated with pulmonary lymphangitis, contained acid-fast bacilli even following aggressive chemotherapy. The presence of intact extracellular bacilli within these lesions suggests that these could serve as the primary sites of disease reactivation. The chemotherapy reduced the level of T-cell influx into infected tissues and was accompanied by a large and sustained increase in TH1 cytokine expression. Chemotherapy also prevented the emergence in lung tissues of high levels of interleukin-10 and Foxp3-positive cells, known markers of regulatory T cells.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20160055      PMCID: PMC2863665          DOI: 10.1128/AAC.01521-09

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  46 in total

Review 1.  Disease model: pulmonary tuberculosis.

Authors:  D N McMurray
Journal:  Trends Mol Med       Date:  2001-03       Impact factor: 11.951

2.  Magnetic resonance imaging of pulmonary lesions in guinea pigs infected with Mycobacterium tuberculosis.

Authors:  Susan L Kraft; Deanna Dailey; Matthew Kovach; Karen L Stasiak; Jamie Bennett; Christine T McFarland; David N McMurray; Angelo A Izzo; Ian M Orme; Randall J Basaraba
Journal:  Infect Immun       Date:  2004-10       Impact factor: 3.441

3.  Histochemical identification of guinea-pig macrophages by monoclonal antibody MR-1.

Authors:  G Kraal; R Shiamatey-Koolma; M Hoffer; D Baker; R Scheper
Journal:  Immunology       Date:  1988-12       Impact factor: 7.397

4.  The sterilizing value of rifampicin and pyrazinamide in experimental short-course chemotherapy.

Authors:  J Grosset
Journal:  Bull Int Union Tuberc       Date:  1978-03

5.  Characterization of guinea-pig group 1 CD1 proteins.

Authors:  Kenji Hiromatsu; Christopher C Dascher; Masahiko Sugita; Cindy Gingrich-Baker; Samuel M Behar; Kenneth P LeClair; Michael B Brenner; Steven A Porcelli
Journal:  Immunology       Date:  2002-06       Impact factor: 7.397

6.  Production of monoclonal antibodies defining guinea pig T-cell surface markers and a strain 13 Ia-like antigen: the value of immunohistological screening.

Authors:  B T Tan; F Ekelaar; J Luirink; G Rimmelzwaan; A J De Jonge; R J Scheper
Journal:  Hybridoma       Date:  1985

7.  The antituberculosis drug pyrazinamide affects the course of cutaneous leishmaniasis in vivo and increases activation of macrophages and dendritic cells.

Authors:  Susana Mendez; Ryan Traslavina; Meleana Hinchman; Lu Huang; Patricia Green; Michael H Cynamon; John T Welch
Journal:  Antimicrob Agents Chemother       Date:  2009-09-21       Impact factor: 5.191

Review 8.  M. tuberculosis persistence, latency, and drug tolerance.

Authors:  James E Gomez; John D McKinney
Journal:  Tuberculosis (Edinb)       Date:  2004       Impact factor: 3.131

9.  Coordinate cytokine gene expression in vivo following induction of tuberculous pleurisy in guinea pigs.

Authors:  Shannon Sedberry Allen; David N McMurray
Journal:  Infect Immun       Date:  2003-08       Impact factor: 3.441

10.  Differential expression of guinea pig class II major histocompatibility complex antigens on vascular endothelial cells in vitro and in experimental allergic encephalomyelitis.

Authors:  C E Wilcox; D Baker; C Butter; D A Willoughby; J L Turk
Journal:  Cell Immunol       Date:  1989-04-15       Impact factor: 4.868

View more
  42 in total

1.  Vaccination of guinea pigs using mce operon mutants of Mycobacterium tuberculosis.

Authors:  Andrés Obregón-Henao; Crystal Shanley; María Verónica Bianco; Angel A Cataldi; Randall J Basaraba; Ian M Orme; Fabiana Bigi
Journal:  Vaccine       Date:  2011-04-22       Impact factor: 3.641

2.  Activity of pyrazinamide in the guinea pig model of tuberculosis.

Authors:  Denis A Mitchison
Journal:  Antimicrob Agents Chemother       Date:  2010-12       Impact factor: 5.191

3.  Dose-dependent activity of pyrazinamide in animal models of intracellular and extracellular tuberculosis infections.

Authors:  Zahoor Ahmad; Mostafa M Fraig; Gregory P Bisson; Eric L Nuermberger; Jacques H Grosset; Petros C Karakousis
Journal:  Antimicrob Agents Chemother       Date:  2011-01-31       Impact factor: 5.191

4.  Inhaled Pyrazinoic Acid Esters for the Treatment of Tuberculosis.

Authors:  E F Young; E Perkowski; S Malik; J D Hayden; P G Durham; L Zhong; J T Welch; Miriam S Braunstein; Anthony J Hickey
Journal:  Pharm Res       Date:  2016-06-28       Impact factor: 4.200

Review 5.  Development of new vaccines and drugs for TB: limitations and potential strategic errors.

Authors:  Ian M Orme
Journal:  Future Microbiol       Date:  2011-02       Impact factor: 3.165

6.  A review of computational and mathematical modeling contributions to our understanding of Mycobacterium tuberculosis within-host infection and treatment.

Authors:  Denise Kirschner; Elsje Pienaar; Simeone Marino; Jennifer J Linderman
Journal:  Curr Opin Syst Biol       Date:  2017-05-22

7.  Increased Foxp3 expression in guinea pigs infected with W-Beijing strains of M. tuberculosis.

Authors:  Shaobin Shang; Marisa Harton; Marcela Henao Tamayo; Crystal Shanley; Gopinath S Palanisamy; Megan Caraway; Edward D Chan; Randall J Basaraba; Ian M Orme; Diane J Ordway
Journal:  Tuberculosis (Edinb)       Date:  2011-07-06       Impact factor: 3.131

8.  Evaluation of a mouse model of necrotic granuloma formation using C3HeB/FeJ mice for testing of drugs against Mycobacterium tuberculosis.

Authors:  Emily R Driver; Gavin J Ryan; Donald R Hoff; Scott M Irwin; Randall J Basaraba; Igor Kramnik; Anne J Lenaerts
Journal:  Antimicrob Agents Chemother       Date:  2012-04-02       Impact factor: 5.191

9.  Copper resistance is essential for virulence of Mycobacterium tuberculosis.

Authors:  Frank Wolschendorf; David Ackart; Tej B Shrestha; Laurel Hascall-Dove; Scott Nolan; Gyanu Lamichhane; Ying Wang; Stefan H Bossmann; Randall J Basaraba; Michael Niederweis
Journal:  Proc Natl Acad Sci U S A       Date:  2011-01-04       Impact factor: 11.205

Review 10.  Opening Pandora's Box: Mechanisms of Mycobacterium tuberculosis Resuscitation.

Authors:  Ashley V Veatch; Deepak Kaushal
Journal:  Trends Microbiol       Date:  2017-09-11       Impact factor: 17.079

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.